Clinical Research Directory
Browse clinical research sites, groups, and studies.
Ate-Bev Early Response Prediction Model in Advanced HCC
Sponsor: Seoul National University Hospital
Summary
The prognosis of hepatocellular carcinoma is poor compared to other carcinomas. Many drugs have recently been developed, and recently, atezolizumab-bevacizumab treatment was superior to sorafenib, the conventional treatment for advanced hepatocellular carcinoma. However, there is no information on the evaluation on the evaluation of treatment response for atezolizumab-bevacizumab combination therapy compared to atezolizumab alone or bevacizumab alone. Therefore, this study aimed to create a predictive model that can detect treatment response at an early stage.
Official title: Developing Atezolizumab-Bevacizumab Treatment Response Early Prediction Model in Advanced Hepatocellular Carcinoma Patients
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
OBSERVATIONAL
Enrollment
170
Start Date
2022-07-22
Completion Date
2026-12-31
Last Updated
2025-05-15
Healthy Volunteers
Yes
Interventions
Early response evaluation
Atezolizumab and bevacizumab are administered every three weeks, and before to the second treatment cycle, blood tests and imaging tests are conducted (week 5). This precedes the standard response evaluation (week 9-12).
Locations (1)
Seoul National University Hospital
Seoul, South Korea